Clinical trial
Pharmacokinetic Study of Tesmilifene (YMB1002) Plus Epirubicin and…
NCT00364754 · YM BioSciences, Industry · Completed
Key facts
| NCT number | NCT00364754 |
|---|---|
| Title | Pharmacokinetic Study of Tesmilifene (YMB1002) Plus Epirubicin and Cyclophosphamide in Metastatic Breast Cancer |
| Official title | A PHARMACOKINETIC INTERACTION PHASE I, MULTI-CENTRE, OPEN-LABEL, CROSS-OVER Study Evaluating the Effect of Tesmilifene on the Plasma Pharmacokinetics of Epirubicin and Cyclophosphamide in Patients With Metastatic/Recurrent Breast Cancer |
| Lead sponsor | YM BioSciences, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Metastatic/Recurrent Breast Cancer |
| Intervention type | Drug |
| Interventions | Tesmilifene (YMB 1002) |
| Enrollment | 28 |
| Start date | May 1, 2004 |
| Primary completion | Jan 1, 2006 |
| Completion | Jan 1, 2006 |
| First posted | Aug 16, 2006 |
| Last update posted | Apr 21, 2014 |
| Countries | Georgia, Russia, Ukraine |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: